拉索昔芬用于治疗绝经后骨质疏松症女性。 - Suppr

Suppr

超能文献

Lasofoxifene for postmenopausal women with osteoporosis.

作者信息

Malozowski Saul

出版信息

N Engl J Med. 2010 Jun 10;362(23):2227; author reply 2228-9. doi: 10.1056/NEJMc1003454.

DOI:10.1056/NEJMc1003454

PMID:20558377

Abstract

摘要

相似文献

Lasofoxifene for postmenopausal women with osteoporosis.

N Engl J Med. 2010 Jun 10;362(23):2227; author reply 2228-9. doi: 10.1056/NEJMc1003454.

Lasofoxifene for postmenopausal women with osteoporosis.

N Engl J Med. 2010 Jun 10;362(23):2228; author reply 2228-9.

Lasofoxifene: new drug. Osteoporosis: no better than raloxifene.

Prescrire Int. 2009 Dec;18(104):247.

Lasofoxifene in postmenopausal women with osteoporosis.

N Engl J Med. 2010 Feb 25;362(8):686-96. doi: 10.1056/NEJMoa0808692.

Another selective estrogen-receptor modulator for osteoporosis.

N Engl J Med. 2010 Feb 25;362(8):752-4. doi: 10.1056/NEJMe0912847.

Lasofoxifene: selective estrogen receptor modulator for the prevention and treatment of postmenopausal osteoporosis.

Ann Pharmacother. 2011 Apr;45(4):499-509. doi: 10.1345/aph.1P604. Epub 2011 Apr 5.

Not all SERMs are created equal.

Menopause. 2006 May-Jun;13(3):325-7. doi: 10.1097/01.gme.0000222332.31101.42.

Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene.

Menopause. 2006 May-Jun;13(3):377-86. doi: 10.1097/01.gme.0000188736.69617.4f.

[Absolute risk for fracture and WHO guideline. Selection of drugs for the prevention of fractures in postmenopausal women].

Clin Calcium. 2007 Jul;17(7):1090-6.

Lasofoxifene for postmenopausal women with osteoporosis.

N Engl J Med. 2010 Jun 10;362(23):2227-8; author reply 2228-9.

引用本文的文献

Osteoporosis: A Review of Treatment Options.

P T. 2018 Feb;43(2):92-104.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Lasofoxifene for postmenopausal women with osteoporosis.

作者信息

Malozowski Saul

出版信息

N Engl J Med. 2010 Jun 10;362(23):2227; author reply 2228-9. doi: 10.1056/NEJMc1003454.

DOI:10.1056/NEJMc1003454

PMID:20558377

Abstract

摘要

相似文献

Lasofoxifene for postmenopausal women with osteoporosis.

N Engl J Med. 2010 Jun 10;362(23):2227; author reply 2228-9. doi: 10.1056/NEJMc1003454.

Lasofoxifene for postmenopausal women with osteoporosis.

N Engl J Med. 2010 Jun 10;362(23):2228; author reply 2228-9.

Lasofoxifene: new drug. Osteoporosis: no better than raloxifene.

Prescrire Int. 2009 Dec;18(104):247.

Lasofoxifene in postmenopausal women with osteoporosis.

N Engl J Med. 2010 Feb 25;362(8):686-96. doi: 10.1056/NEJMoa0808692.

Another selective estrogen-receptor modulator for osteoporosis.

N Engl J Med. 2010 Feb 25;362(8):752-4. doi: 10.1056/NEJMe0912847.

Lasofoxifene: selective estrogen receptor modulator for the prevention and treatment of postmenopausal osteoporosis.

Ann Pharmacother. 2011 Apr;45(4):499-509. doi: 10.1345/aph.1P604. Epub 2011 Apr 5.

Not all SERMs are created equal.

Menopause. 2006 May-Jun;13(3):325-7. doi: 10.1097/01.gme.0000222332.31101.42.

Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene.

Menopause. 2006 May-Jun;13(3):377-86. doi: 10.1097/01.gme.0000188736.69617.4f.

[Absolute risk for fracture and WHO guideline. Selection of drugs for the prevention of fractures in postmenopausal women].

Clin Calcium. 2007 Jul;17(7):1090-6.

Lasofoxifene for postmenopausal women with osteoporosis.

N Engl J Med. 2010 Jun 10;362(23):2227-8; author reply 2228-9.

引用本文的文献

Osteoporosis: A Review of Treatment Options.

P T. 2018 Feb;43(2):92-104.